Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Almirall S.A.
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
February 19, 2024
From
Almirall S.A.
Via
Business Wire
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
November 17, 2023
From
Almirall S.A.
Via
Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
November 14, 2023
From
Almirall S.A.
Via
Business Wire
Tickers
ABSI
Almirall’s Nine-month 2023 Results:
November 09, 2023
From
Almirall S.A.
Via
Business Wire
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
October 13, 2023
From
Almirall S.A.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.